Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.7K Sell
72,038
-530,852
-88% -$516K ﹤0.01% 6424
2025
Q4
$609K Buy
602,890
+474,959
+371% +$674K ﹤0.01% 5412
2025
Q3
$164K Buy
+127,931
New +$167K ﹤0.01% 5965
2025
Q1
Sell
-9,800
Closed -$17.6K 8181
2024
Q4
$17.6K Buy
+9,800
New +$19K ﹤0.01% 6607
2024
Q1
Sell
-5,600
Closed -$10.9K 7926
2023
Q4
$10.9K Buy
5,600
+5,550
+11,100% +$10.4K ﹤0.01% 6820
2023
Q3
$107 Sell
50
-941
-95% -$2.35K ﹤0.01% 7440
2023
Q2
$2.63K Buy
991
+841
+561% +$2.35K ﹤0.01% 7135
2023
Q1
$540 Sell
150
-1,483
-91% -$6.5K ﹤0.01% 7419
2022
Q4
$6.7K Buy
1,633
+1,519
+1,332% +$8.74K ﹤0.01% 7073
2022
Q3
$0 Sell
114
-636
-85% -$4.24K ﹤0.01% 7821
2022
Q2
$5K Buy
750
+700
+1,400% +$8.68K ﹤0.01% 7404
2022
Q1
$1K Buy
+50
New +$825 ﹤0.01% 7856

Other funds holding NVX

Morgan Stanley's NVX Position: Q1 2026 in Review

Morgan Stanley reduced its NOVONIX (NVX) stake by 88% in Q1 2026, selling an estimated $516K and leaving 72,038 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6424.

Morgan Stanley first reported a position in NVX in Q1 2022 and has held it in 12 quarters since. The position peaked at $609K in Q4 2025. 32 funds tracked by Wall St. Rank hold NVX as of Q1 2026.

  • Morgan Stanley held 72,038 shares of NOVONIX worth $49.7K as of Q1 2026.
  • Morgan Stanley sold 530,852 NOVONIX shares in Q1 2026, an estimated $516K.
  • NOVONIX made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6424 holding.
  • Morgan Stanley first reported a position in NOVONIX in Q1 2022 and has held it in 12 quarters since.
  • Morgan Stanley's NOVONIX position peaked at $609K in Q4 2025.
  • 32 funds tracked by Wall St. Rank held NOVONIX as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.